Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations von Subbiah, V., Shen, T., Terzyan, S.S., Liu, X., Hu, X., Patel, K.P., Hu, M., Cabanillas, M., Behrang, A., Meric-Bernstam, F., Vo, P.T.T., Mooers, B.H.M., Wu, J.

Volltext

Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study von Kurzrock, R., Bowles, D.W., Kang, H., Meric-Bernstam, F., Hainsworth, J., Spigel, D.R., Bose, R., Burris, H., Sweeney, C.J., Beattie, M.S., Blotner, S., Schulze, K., Cuchelkar, V., Swanton, C.

Volltext

Which threshold for ER positivity? a retrospective study based on 9639 patients von Yi, M., Huo, L., Koenig, K.B., Mittendorf, E.A., Meric-Bernstam, F., Kuerer, H.M., Bedrosian, I., Buzdar, A.U., Symmans, W.F., Crow, J.R., Bender, M., Shah, R.R., Hortobagyi, G.N., Hunt, K.K.

Volltext

Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer von Liedtke, C., Broglio, K., Moulder, S., Hsu, L., Kau, S.-W., Symmans, W.F., Albarracin, C., Meric-Bernstam, F., Woodward, W., Theriault, R.L., Kiesel, L., Hortobagyi, G.N., Pusztai, L., Gonzalez-Angulo, A.M.

Volltext

Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group von Mosele, F., Remon, J., Mateo, J., Westphalen, C.B., Barlesi, F., Lolkema, M.P., Normanno, N., Scarpa, A., Robson, M., Meric-Bernstam, F., Wagle, N., Stenzinger, A., Bonastre, J., Bayle, A., Michiels, S., Bièche, I., Rouleau, E., Jezdic, S., Douillard, J-Y., Reis-Filho, J.S., Dienstmann, R., André, F.

Volltext

Efficient clinical research infrastructure and trial performance: Assessment of a dedicated clinical trials unit within an academic cancer center von Tang, C, Hess, K, Sanders, D, Davis, S, Kurzrock, R, Lee, J.J, Meric Bernstam, F, Hong, D

Volltext

Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1–4 inhibitor in patients with advanced solid tumors von Bahleda, R., Meric-Bernstam, F., Goyal, L., Tran, B., He, Y., Yamamiya, I., Benhadji, K.A., Matos, I., Arkenau, H.-T.

Volltext

High prevalence of mutant KRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients von Allenson, K, Castillo, J, San Lucas, F A, Scelo, G, Kim, D U, Bernard, V, Davis, G, Kumar, T, Katz, M, Overman, M J, Foretova, L, Fabianova, E, Holcatova, I, Janout, V, Meric-Bernstam, F, Gascoyne, P, Wistuba, I, Varadhachary, G, Brennan, P, Hanash, S, Li, D, Maitra, A, Alvarez, H

Volltext

Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study von Hong, D.S., Bauer, T.M., Lee, J.J., Dowlati, A., Brose, M.S., Farago, A.F., Taylor, M., Shaw, A.T., Montez, S., Meric-Bernstam, F., Smith, S., Tuch, B.B., Ebata, K., Cruickshank, S., Cox, M.C., Burris, H.A., Doebele, R.C.

Volltext

Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group von Mosele, M.F., Westphalen, C.B., Stenzinger, A., Barlesi, F., Bayle, A., Bièche, I., Bonastre, J., Castro, E., Dienstmann, R., Krämer, A., Czarnecka, A.M., Meric-Bernstam, F., Michiels, S., Miller, R., Normanno, N., Reis-Filho, J., Remon, J., Robson, M., Rouleau, E., Scarpa, A., Serrano, C., Mateo, J., André, F.

Volltext

Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol von Meric-Bernstam, F., Brusco, L., Daniels, M., Wathoo, C., Bailey, A.M., Strong, L., Shaw, K., Lu, K., Qi, Y., Zhao, H., Lara-Guerra, H., Litton, J., Arun, B., Eterovic, A.K., Aytac, U., Routbort, M., Subbiah, V., Janku, F., Davies, M.A., Kopetz, S., Mendelsohn, J., Mills, G.B., Chen, K.

Volltext

Patient-driven discovery and post-clinical validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive lung cancer von Subbiah, V., Shen, T., Tetzlaff, M., Weissferdt, A., Byers, L.A., Cascone, T., Behrang, A., Meric-Bernstam, F., Mooers, B.H.M., Rothenberg, S.M., Ebata, K., Wu, J.

Volltext

Weight gain in patients with RET aberrant cancers treated with brain penetrant RET selective inhibitors von Gouda, M.A., Hu, M.I., Cabanillas, M.E., Wu, J., Meric-Bernstam, F., Subbiah, V.

Volltext

Genomic correlates of response and resistance to the irreversible FGFR1-4 inhibitor futibatinib based on biopsy and circulating tumor DNA profiling von Goyal, L, DiToro, D, Hollebecque, A, Bridgewater, J A, Shimura, M, Kano, A, Okamura, S, Silhavy, J L, Wacheck, V, Halim, A, Meric-Bernstam, F

Volltext

Targeted methylation sequencing of plasma cell-free DNA for cancer detection and classification von Liu, L., Toung, J.M., Jassowicz, A.F., Vijayaraghavan, R., Kang, H., Zhang, R., Kruglyak, K.M., Huang, H.J., Hinoue, T., Shen, H., Salathia, N.S., Hong, D.S., Naing, A., Subbiah, V., Piha-Paul, S.A., Bibikova, M., Granger, G., Barnes, B., Shen, R., Gutekunst, K., Fu, S., Tsimberidou, A.M., Lu, C., Eng, C., Moulder, S.L., Kopetz, E.S., Amaria, R.N., Meric-Bernstam, F., Laird, P.W., Fan, J.-B., Janku, F.

Volltext

HER2-low expression in patients with advanced or metastatic solid tumors von Uzunparmak, B., Haymaker, C., Raso, G., Masciari, S., Wang, L., Lin, H., Gorur, A., Kirby, B., Cimo, A.-M., Kennon, A., Ding, Q., Urschel, G., Yuan, Y., Feng, G., Rizvi, Y., Hussain, A., Zhu, C., Kim, P., Abbadessa, G., Subbiah, V., Yap, T.A., Rodon, J., Piha-Paul, S.A., Meric-Bernstam, F., Dumbrava, E.E.

Volltext

Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study von Curigliano, G, Gómez Pardo, P, Meric-Bernstam, F, Conte, P, Lolkema, M.P, Beck, J.T, Bardia, A, Martínez García, M, Penault-Llorca, F, Dhuria, S, Tang, Z, Solovieff, N, Miller, M, Di Tomaso, E, Hurvitz, S.A

Volltext

Vertical inhibition of the PI3K/Akt/mTOR pathway is synergistic in breast cancer von Woo, S-U, Sangai, T, Akcakanat, A, Chen, H, Wei, C, Meric-Bernstam, F

Volltext

Genomic characterization of HER2-positive breast cancer and response to neoadjuvant trastuzumab and chemotherapy—results from the ACOSOG Z1041 (Alliance) trial von Lesurf, R., Griffith, O.L., Griffith, M., Hundal, J., Trani, L., Watson, M.A., Aft, R., Ellis, M.J., Ota, D., Suman, V.J., Meric-Bernstam, F., Leitch, A.M., Boughey, J.C., Unzeitig, G., Buzdar, A.U., Hunt, K.K., Mardis, E.R.

Volltext

Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation von Fu, S., Hou, M.M., Naing, A., Janku, F., Hess, K., Zinner, R., Subbiah, V., Hong, D., Wheler, J., Piha-Paul, S., Tsimberidou, A., Karp, D., Araujo, D., Kee, B., Hwu, P., Wolff, R., Kurzrock, R., Meric-Bernstam, F.

Volltext